Long-term use of drugs affecting the renin-angiotensin system and the risk of cancer. A population-based case-control study

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Long-term use of drugs affecting the renin-angiotensin system and the risk of cancer. A population-based case-control study. / Hallas, Jesper; Depont Christensen, Rene; Andersen, Morten; Friis, Søren; Bjerrum, Lars.

In: British Journal of Clinical Pharmacology. Supplement, Vol. 74, No. 1, 2012, p. 180-188.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Hallas, J, Depont Christensen, R, Andersen, M, Friis, S & Bjerrum, L 2012, 'Long-term use of drugs affecting the renin-angiotensin system and the risk of cancer. A population-based case-control study', British Journal of Clinical Pharmacology. Supplement, vol. 74, no. 1, pp. 180-188. https://doi.org/10.1111/j.1365-2125.2012.04170.x

APA

Hallas, J., Depont Christensen, R., Andersen, M., Friis, S., & Bjerrum, L. (2012). Long-term use of drugs affecting the renin-angiotensin system and the risk of cancer. A population-based case-control study. British Journal of Clinical Pharmacology. Supplement, 74(1), 180-188. https://doi.org/10.1111/j.1365-2125.2012.04170.x

Vancouver

Hallas J, Depont Christensen R, Andersen M, Friis S, Bjerrum L. Long-term use of drugs affecting the renin-angiotensin system and the risk of cancer. A population-based case-control study. British Journal of Clinical Pharmacology. Supplement. 2012;74(1):180-188. https://doi.org/10.1111/j.1365-2125.2012.04170.x

Author

Hallas, Jesper ; Depont Christensen, Rene ; Andersen, Morten ; Friis, Søren ; Bjerrum, Lars. / Long-term use of drugs affecting the renin-angiotensin system and the risk of cancer. A population-based case-control study. In: British Journal of Clinical Pharmacology. Supplement. 2012 ; Vol. 74, No. 1. pp. 180-188.

Bibtex

@article{6c57ed27f7734535952671590fbc1f18,
title = "Long-term use of drugs affecting the renin-angiotensin system and the risk of cancer. A population-based case-control study",
abstract = "Aims: A recent meta-analysis of clinical trials has demonstrated a small excess of cancers in persons that had been allocated to angiotensin-receptor blockers (ARBs). We undertook this observational study to look at dose-response and dose-duration effects and look for specificity with respect to outcome. Use of angiotensin converting enzyme inhibitors (ACEIs) was included in the main analysis since ACEIs share pharmacological properties with ARBs. Methods: We identified 149,417 incident cancer cases in Denmark during the period 2000-2005. Four controls, matched by age and gender, were selected for each case by a risk-set sampling. Data on medication was retrieved from the Danish National Prescription Registry. We defined long-term exposure as at least 1000 defined daily doses redeemed within the past five years. Confounders were controlled by conditional logistic regression. Results: The odds ratio (OR) associating long-term drug use with incident cancer was 1.12 (95{\%} CI: 1.06-1.18), 1.17 (95{\%} CI: 1.14-1.20), 1.23 (95{\%} CI: 1.20-1.26), 1.18 (95{\%} CI: 1.14-1.22), 1.25 (95{\%} CI: 1.22-1.28), 1.37 (95{\%} CI: 1.21-1.54), 1.29 (95{\%} CI: 1.22-1.37) for ARB, ACEI, calcium channel blockers, beta blockers, thiazide diuretics and alfa blockers. No consistent dose-duration or dose-response association could be demonstrated for ARB or ACEI. Conclusion: The indication or possibly threshold for prescribing antihypertensives appears to be related to a small increase in cancer risk. The ARB-cancer association is probably too weak to be addressed in observational studies, given their limitations. {\circledC} 2012 The Authors. British Journal of Clinical Pharmacology {\circledC} 2012 The British Pharmacological Society.",
author = "Jesper Hallas and {Depont Christensen}, Rene and Morten Andersen and S{\o}ren Friis and Lars Bjerrum",
note = "{\circledC} 2012 The Authors. British Journal of Clinical Pharmacology {\circledC} 2012 The British Pharmacological Society.",
year = "2012",
doi = "10.1111/j.1365-2125.2012.04170.x",
language = "English",
volume = "74",
pages = "180--188",
journal = "British Journal of Clinical Pharmacology. Supplement",
issn = "0264-3774",
publisher = "Wiley-Blackwell",
number = "1",

}

RIS

TY - JOUR

T1 - Long-term use of drugs affecting the renin-angiotensin system and the risk of cancer. A population-based case-control study

AU - Hallas, Jesper

AU - Depont Christensen, Rene

AU - Andersen, Morten

AU - Friis, Søren

AU - Bjerrum, Lars

N1 - © 2012 The Authors. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society.

PY - 2012

Y1 - 2012

N2 - Aims: A recent meta-analysis of clinical trials has demonstrated a small excess of cancers in persons that had been allocated to angiotensin-receptor blockers (ARBs). We undertook this observational study to look at dose-response and dose-duration effects and look for specificity with respect to outcome. Use of angiotensin converting enzyme inhibitors (ACEIs) was included in the main analysis since ACEIs share pharmacological properties with ARBs. Methods: We identified 149,417 incident cancer cases in Denmark during the period 2000-2005. Four controls, matched by age and gender, were selected for each case by a risk-set sampling. Data on medication was retrieved from the Danish National Prescription Registry. We defined long-term exposure as at least 1000 defined daily doses redeemed within the past five years. Confounders were controlled by conditional logistic regression. Results: The odds ratio (OR) associating long-term drug use with incident cancer was 1.12 (95% CI: 1.06-1.18), 1.17 (95% CI: 1.14-1.20), 1.23 (95% CI: 1.20-1.26), 1.18 (95% CI: 1.14-1.22), 1.25 (95% CI: 1.22-1.28), 1.37 (95% CI: 1.21-1.54), 1.29 (95% CI: 1.22-1.37) for ARB, ACEI, calcium channel blockers, beta blockers, thiazide diuretics and alfa blockers. No consistent dose-duration or dose-response association could be demonstrated for ARB or ACEI. Conclusion: The indication or possibly threshold for prescribing antihypertensives appears to be related to a small increase in cancer risk. The ARB-cancer association is probably too weak to be addressed in observational studies, given their limitations. © 2012 The Authors. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society.

AB - Aims: A recent meta-analysis of clinical trials has demonstrated a small excess of cancers in persons that had been allocated to angiotensin-receptor blockers (ARBs). We undertook this observational study to look at dose-response and dose-duration effects and look for specificity with respect to outcome. Use of angiotensin converting enzyme inhibitors (ACEIs) was included in the main analysis since ACEIs share pharmacological properties with ARBs. Methods: We identified 149,417 incident cancer cases in Denmark during the period 2000-2005. Four controls, matched by age and gender, were selected for each case by a risk-set sampling. Data on medication was retrieved from the Danish National Prescription Registry. We defined long-term exposure as at least 1000 defined daily doses redeemed within the past five years. Confounders were controlled by conditional logistic regression. Results: The odds ratio (OR) associating long-term drug use with incident cancer was 1.12 (95% CI: 1.06-1.18), 1.17 (95% CI: 1.14-1.20), 1.23 (95% CI: 1.20-1.26), 1.18 (95% CI: 1.14-1.22), 1.25 (95% CI: 1.22-1.28), 1.37 (95% CI: 1.21-1.54), 1.29 (95% CI: 1.22-1.37) for ARB, ACEI, calcium channel blockers, beta blockers, thiazide diuretics and alfa blockers. No consistent dose-duration or dose-response association could be demonstrated for ARB or ACEI. Conclusion: The indication or possibly threshold for prescribing antihypertensives appears to be related to a small increase in cancer risk. The ARB-cancer association is probably too weak to be addressed in observational studies, given their limitations. © 2012 The Authors. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society.

U2 - 10.1111/j.1365-2125.2012.04170.x

DO - 10.1111/j.1365-2125.2012.04170.x

M3 - Journal article

C2 - 22243442

VL - 74

SP - 180

EP - 188

JO - British Journal of Clinical Pharmacology. Supplement

JF - British Journal of Clinical Pharmacology. Supplement

SN - 0264-3774

IS - 1

ER -

ID: 37391329